MCGAULEY THOMAS
Known title: Interim CFOCIK: 0001550701
MCGAULEY THOMAS's purchase track record
MCGAULEY THOMAS has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/17/2025 | TENX | $58K | +69.8% | +58.1% | +10.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TENX | ▲ Buy | Open Market | 2,000 | $15K | 11/17/2025 | View on chart |
| TENX | ▲ Buy | Open Market | 1,000 | $7K | 11/17/2025 | View on chart |
| TENX | ▲ Buy | Open Market | 5,000 | $36K | 11/17/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Tenax Pauses TNX-103 Trial Enrollment, Seeks FDA Meeting
Tenax Therapeutics has temporarily paused enrollment in its LEVEL-2 trial for TNX-103 to amend study criteria. The company has also requested a meeting with the FDA to discuss these changes. This development is significant as it involves a key clinical trial, and the stock is currently trading near its 52-week low.
Tenax Pauses TNX-103 Trial Enrollment, Seeks FDA Meeting. Tenax Therapeutics has temporarily paused enrollment in its LEVEL-2 trial for TNX-103 to amend study criteria. The company has also requested a meeting with the FDA to discuss these changes. This development is significant as it involves a key clinical trial, and the stock is currently trading near its 52-week low.